GlaxoSmithKline has discontinued development of GSK2251052 following a recent clinical trial that was stopped due to the identification of microbiological findings of resistance in a small number of patients undergoing treatment of complicated urinary tract infections (cUTI). GSK has decided to discontinue further development of GSK2251052 and return all rights to Anacor.
 
Anacor Pharmaceuticals licensed the drug to GSK in July 2010 under an ongoing R&D collaboration. GSK is continuing to fund Anacor’s research activities in tuberculosis as under the companies’ amended R&D collaboration.